Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBSNM Nerve Fiber Density Testing Coverage | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - New MexicoPolicy CPCPLAB064

    Nerve Fiber Density Testing

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy CPCPLAB064 alerts

    Get alerted when Policy CPCPLAB064 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs reimbursement criteria for epidermal nerve fiber density testing (skin biopsy) and related nerve fiber density measurements for Blue Cross Blue Shield - New Mexico members and providers submitting claims under BCBSNM plans.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyNerve Fiber Density Testing
    Policy CodePolicy CPCPLAB064
    Change TypeNo material change — reimbursement info unchanged in most recent update
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation and respond to requests for additional documentation; claims are subject to review and coding edits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All 4 criteriaENFD reimbursable when
    Sweat gland ENFDNot reimbursable

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7 listed
    Procedure codes referenced
    May 1, 2026Policy effective
    3 notedHistorical coding edits

    Coverage Criteria for ENFD

    ENFD coverage criteria

    Reimbursement for epidermal nerve fiber density (ENFD) measurement from a skin biopsy is provided only when ALL of the following are met; sweat gland nerve fiber density measurement is not reimbursable.

    ALL of the following

    • ALL of the following

      • Patient presents with symptoms of painful sensory neuropathy

        Symptom-based indication required

    • ALL of the following

      • No history of a disorder known to predispose to painful neuropathy (e.g., diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy)

        Exclude common predisposing conditions

    • ALL of the following

      • Physical exam shows no evidence of findings consistent with large-fiber neuropathy (e.g., reduced or absent muscle-stretch reflexes or reduced proprioception and vibration sensation)

        Exam must not demonstrate large-fiber signs

    • ALL of the following

      • Electromyography and nerve-conduction studies are normal and show no evidence of large-fiber neuropathy

        Normal EMG/NCS required to support small-fiber neuropathy evaluation

    ALL of the following

    • Epidermal nerve fiber density measurement is not reimbursable for situations not meeting the above criteria

      Claims without all required criteria should not be reimbursed

    • Measurement of sweat gland nerve fiber density is not reimbursable

      Sweat gland nerve fiber density explicitly excluded from reimbursement

    Coverage and update summary

    Policy update history and summary of recent changes; reimbursement information was reported as unchanged in the most recent updates.

    ALL of the following

    • 01/12/2026 (effective 05/01/2026): Document updated with literature review; Reimbursement Information unchanged; References revised.
    • 10/30/2024 (effective 01/15/2025): Document updated with literature review; Reimbursement Information unchanged; References revised.
    • 03/01/2024 (effective 03/01/2024): Document updated with literature review; Reimbursement Information revised for clarity; Added code 88313; removed codes 88305, 88314; References revised.
    • 11/01/2023 (effective 11/01/2023): Document updated with literature review; Reimbursement information revised for clarity; References revised.
    • 11/01/2022 (effective 11/01/2022): New policy.

    Indications Covered by Policy

    Evaluation for small-fiber neuropathy (painful sensory neuropathy)

    Covered indication: evaluation for small-fiber neuropathy (painful sensory neuropathy) when ALL specified clinical, historical, physical exam, and electrodiagnostic criteria are met.

    ALL of the following

    • ALL of the following

      • Patient presents with symptoms of painful sensory neuropathy

    • ALL of the following

      • No history of a disorder known to predispose to painful neuropathy (e.g., diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy)

    • ALL of the following

    Procedure Codes and Coding History

    Procedure codes mentionedCPT
    8831388313
    8834188341
    8834288342
    8834488344
    8834688346
    8835088350
    8835688356
    Procedure codes mentioned (display note)mixed
    No codes listed
    Historical coding changesCPT
    88313Code added to policy in 03/01/2024 update
    88305Code removed from policy in 03/01/2024 update
    88314Code removed from policy in 03/01/2024 update
    Policy update summary (coding)mixed
    No codes listed
    Reimbursement information changes — recent updates
    Recent update statusMost recent updates (01/12/2026 and 10/30/2024) state: 'Reimbursement Information unchanged.'
    Earlier revisions03/01/2024 and 11/01/2023 updates noted 'Reimbursement Information revised for clarity.'
    Coding changes noted in history03/01/2024 update: added code 88313 and removed codes 88305 and 88314.
    Document maintenancePolicy updated with literature reviews on multiple dates; references were revised in each update.

    Provider Responsibilities and Billing

    Documentation Required

    Submit accurate documentation and respond to documentation requests

    Providers are responsible for submission of accurate documentation of services performed and must code claims using valid HIPAA-approved code sets and industry-standard guidelines; claims are subject to code edit protocols and review. Upon request, providers are urged to submit any additional documentation to support the claim.

    • Use valid code combinations from HIPAA-approved code sets (e.g., CPT, HCPCS, ICD-10-CM).
    • Follow industry standard coding guidelines (Uniform Billing Editor, AMA CPT Assistant, CMS NCCI edits, etc.).
    • Claims may be reviewed against benefit coverage, provider contract terms, medical and clinical payment policies, and coding software logic.
    Billing Rule

    Definitions and References

    ENFD reimbursable criteria definition
    Test definedEpidermal nerve fiber density (ENFD) measurement from a skin biopsy.
    Primary clinical purposeEvaluation for small-fiber (painful sensory) neuropathy when specific clinical, historical, and electrodiagnostic criteria are met.
    Required conditions for reimbursementReimbursable only when ALL conditions met: (a) symptoms of painful sensory neuropathy; (b) no history of disorders known to predispose to painful neuropathy; (c) physical exam shows no evidence of large-fiber neuropathy; (d) electromyography and nerve-conduction studies are normal.
    Not reimbursableMeasurement of sweat gland nerve fiber density is explicitly not reimbursable.
    References
    ADA Standards (Diabetes care 2020)

    Ordering and Authorization Requirements

    Note

    Follow plan and contract requirements for ordering and submit required documentation

    The policy does not specify who may order testing; providers must follow applicable plan documents and their provider contract when ordering and must submit the documentation required by the plan or contract.

    • Follow plan documents (Certificates of Benefits, benefit booklets, Summary Plan Descriptions) and your provider contract to determine ordering privileges.
    • Submit supporting documentation as requested by the plan per documentation and claims submission requirements.

    Services Not Covered

    Epidermal nerve fiber density (ENFD) testing from a skin biopsy is reimbursable only when ALL of the following are met: the patient presents with symptoms of painful sensory neuropathy; there is no history of a disorder known to predispose to painful neuropathy (for example, diabetic, toxic, HIV-related, celiac, or inherited neuropathy); the physical examination shows no evidence of large‑fiber neuropathy (such as reduced/absent reflexes or reduced proprioception/vibration); and electromyography and nerve‑conduction studies are normal with no evidence of large‑fiber neuropathy. For any situations that do not meet these enumerated criteria, ENFD testing is not reimbursable.

    Measurement of sweat gland nerve fiber density is explicitly not reimbursable. In addition, the policy states that ENFD testing is not reimbursable for all other situations not described in the specified coverage criteria.

    Frequency Limits

    Frequency limits
    Stated frequency limitsNo specific frequency limits are provided in the policy (frequency limit fields are blank).
    Policy update note relevant to frequencyPolicy update history entries show multiple literature-review updates but do not add frequency or periodicity limits.
    Action for providersFollow plan-specific benefit documents for any applicable frequency limitations, as the policy itself does not specify a limit.
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyNerve Fiber Density Testing
    Policy CodePolicy CPCPLAB064
    Change TypeNo material change — reimbursement info unchanged in most recent update
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation and respond to requests for additional documentation; claims are subject to review and coding edits.
    SourceLink
    On This Page
    Coverage Criteria for ENFDIndications Covered by PolicyProcedure Codes and Coding HistoryProvider Responsibilities and BillingDefinitions and ReferencesOrdering and Authorization RequirementsServices Not CoveredFrequency Limits

    ALL of the following

    • Reimbursement Information unchanged in the most recent updates (01/12/2026 and 10/30/2024).
    Physical exam shows no evidence of findings consistent with large-fiber neuropathy (e.g., reduced or absent muscle-stretch reflexes or reduced proprioception and vibration sensation)

  1. ALL of the following

    • Electromyography and nerve-conduction studies are normal and show no evidence of large-fiber neuropathy

    2. ALL of the following

    • ENFD testing is not reimbursable for situations that do not meet all the above criteria
    • Sweat gland nerve fiber density measurement is explicitly not reimbursable

    References — diabetes-related neuropathy and neuropathic pain assessment

    References relevant to diabetes-related neuropathy and neuropathic pain assessment cited in support of covered indications.

    ALL of the following

    • ADA. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020 (Diabetes Care).

      Reference supports diabetes-related neuropathy context

    • ADA. Standards of Medical Care in Diabetes (Abridged for Primary Care Providers) — 2019–2023 and 2025 entries cited.

      Multiple ADA abridged standards referenced in policy

    • NeuPSIG guidelines on neuropathic pain assessment (Haanpaa et al., Pain 2011) and other cited studies (e.g., IMMPACT considerations, Burlina et al.).

      References support neuropathic pain assessment and use of skin biopsy as a biomarker

    Be aware of historical coding edits and current reimbursement status

    Reimbursement information for this policy was reported as unchanged in the most recent updates; prior updates documented coding changes (e.g., added CPT code 88313 and removed CPT codes 88305 and 88314) and revisions to reimbursement information that may affect billing and prior authorization workflows.

    • Policy Update History notes: 03/01/2024 update added code 88313 and removed codes 88305 and 88314.
    • Policy Update History entries (10/30/2024 and 01/12/2026) state "Reimbursement Information unchanged."
    ADA. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020 (Diabetes Care Jan 2020;43 Suppl 1:S14-S31).
    ADA Standards (2021–2025 abridged and standards)ADA. Standards of Medical Care in Diabetes-2021 through 2025 and abridged variants (Clinical Diabetes; Diabetes Care), listed as references 62–66 in the policy.
    Neuropathic pain assessment guidelineHaanpaa M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. Jan 2011;152(1):14-27.
    Supportive clinical studies and reportsBurlina et al. on early diagnosis in Fabry disease; Smith et al. on sensory testing/skin biopsy as biomarkers in chronic pain trials (IMMPACT).